Overview

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Status:
RECRUITING

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).

Phase:

PHASE1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

daratumumab
Lenalidomide
pomalidomide